Kura Oncology
Stock
Stock
Ticker: KURA
KURA
Price
Price
CHART BY
Frequently asked questions
What is Kura Oncology's market capitalization?
The market capitalization of Kura Oncology is $878.93M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Kura Oncology?
Kura Oncology's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.362. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Kura Oncology's stock?
Currently, 16 analysts cover Kura Oncology's stock, with a consensus target price of $31.85. Analyst ratings provide insights into the stock's expected performance.
What is Kura Oncology's revenue over the trailing twelve months?
Over the trailing twelve months, Kura Oncology reported a revenue of $77.23M.
What is the EBITDA for Kura Oncology?
Kura Oncology's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$316.80M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Kura Oncology?
Kura Oncology has a free cash flow of -$117.43M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Kura Oncology have, and what sector and industry does it belong to?
Kura Oncology employs approximately 260 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Kura Oncology's shares?
The free float of Kura Oncology is 86.49M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $878.93M
- EPS (TTM)
- -$3.362
- Free Float
- 86.49M
- Revenue (TTM)
- $77.23M
- EBITDA (TTM)
- -$316.80M
- Free Cashflow (TTM)
- -$117.43M
Pricing
- 1D span
- $9.843$9.881
- 52W span
- $7.36$13.89
Analyst Ratings
The price target is $31.85 and the stock is covered by 16 analysts.
Buy
15
Hold
1
Sell
0
Information
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
- Employees
- 260
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- KURA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet